|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM and Shoreibah MG: Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol. 25:1550–1559. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Petruzziello A: Epidemiology of hepatitis B virus (HBV) and hepatitis C Virus (HCV) related hepatocellular carcinoma. Open Virol J. 12:26–32. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu CY, Chen KF and Chen PJ: Treatment of liver cancer. Cold Spring Harb Perspect Med. 5:a0215352015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang EA, Stein JP, Bellavia RJ and Broadwell SR: Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Int J Clin Pract. 71:302017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hartke J, Johnson M and Ghabril M: The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 34:153–159. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Toninello A, Pietrangeli P, De Marchi U, Salvi M and Mondovì B: Amine oxidases in apoptosis and cancer. Biochim Biophys Acta. 1:1–13. 2006.PubMed/NCBI
|
|
8
|
Schwelberger HG: Structural organization of mammalian copper-containing amine oxidase genes. Inflamm Res. 59 (Suppl 2):S223–S235. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun WY, Choi J, Cha YJ and Koo JS: Evaluation of the expression of amine oxidase proteins in breast cancer. Int J Mol Sci. 18:27752017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vakal S, Jalkanen S, Dahlström KM and Salminen TA: Human copper-containing amine oxidases in drug design and development. Molecules. 25:12932020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu F, Xu Y, Xiong JH, Zhang JH, Wu J, Luo J and Xiong JP: AOC1 contributes to tumor progression by promoting the AKT and EMT pathways in gastric cancer. Cancer Manag Res. 12:1789–1798. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nourbakhsh M, Farzaneh S, Taghikhani A, Zarghi A and Noori S: The effect of a newly synthesized ferrocene derivative against MCF-7 breast cancer cells and spheroid stem cells through ROS production and inhibition of JAK2/STAT3 signaling pathway. Anticancer Agents Med Chem. 20:875–886. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao Y, Wang J, Tian H and Fu GH: Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer. J Exp Clin Cancer Res. 39:1192020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li J, Pu T, Yin L, Li Q, Liao CP and Wu BJ: MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness. Oncogene. 39:3305–3321. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee HM, Sia APE, Li L, Sathasivam HP, Chan MSA, Rajadurai P, Tsang CM, Tsao SW, Murray PG, Tao Q, et al: Monoamine oxidase A is down-regulated in EBV-associated nasopharyngeal carcinoma. Sci Rep. 10:61152020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Therneau TM: Survival Analysis [R package survival version 2.41–3]. Technometrics. 46:111–112. 2015.
|
|
17
|
Li ZS and Li Q: The latest 2010 WHO classification of tumors of digestive system. Zhonghua Bing Li Xue Za Zhi. 40:351–354. 2011.(In Chinese). PubMed/NCBI
|
|
18
|
Hoshi T, Watanabe Miyano S, Watanabe H, Sonobe RMK, Seki Y, Ohta E, Nomoto K, Matsui J and Funahashi Y: Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades. Biochem Biophys Res Commun. 513:1–7. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang H, Zhou Z, Jin S, Xu K, Zhang H and Xu J, Sun Q, Wang J and Xu J: PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3β/Snail signaling. Cancer Sci. 109:1414–1427. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Giannelli G, Koudelkova P, Dituri F and Mikulits W: Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 65:798–808. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ivanova ON, Snezhkina AV, Krasnov GS, Valuev-Elliston VT, Khomich OA, Khomutov AR and Keinanen TA: Activation of Polyamine Catabolism by N¹,N11-Diethylnorspermine in Hepatic HepaRG cells induces dedifferentiation and mesenchymal-like phenotype. Cells. 7:2752018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wen B, Xu LY and Li EM: LOXL2 in cancer: Regulation, downstream effectors and novel roles. Biochim Biophys Acta Rev Cancer. 1874:1884352020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moon HJ, Finney J, Xu L, Moore D, Welch DR and Mure M: MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro. J Biol Chem. 288:30000–30008. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moloney JN and Cotter TG: ROS signalling in the biology of cancer. Semin Cell Dev Biol. 80:50–64. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dong Y, Wu Z, He M, Chen Y, Chen Y, Shen X, Zhao X, Zhang L, Yuan B and Zeng Z: ADAM9 mediates the interleukin-6-induced Epithelial-Mesenchymal transition and metastasis through ROS production in hepatoma cells. Cancer Lett. 421:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Binker MG, Binker-Cosen AA, Gaisano HY, de Cosen RH and Cosen-Binker LI: TGF-β1 increases invasiveness of SW1990 cells through Rac1/ROS/NF-κB/IL-6/MMP-2. Biochem Biophys Res Commun. 405:140–145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Y, Yan W, Collins MA, Bednar F, Rakshit S, Zetter BR, Stanger BZ, Chung I, Rhim AD and di Magliano MP: Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 73:6359–6374. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Browning L, Patel MR, Horvath EB, Tawara K and Jorcyk CL: IL-6 and ovarian cancer: Inflammatory cytokines in promotion of metastasis. Cancer Manag Res. 10:6685–6693. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bromberg J and Wang TC: Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell. 15:79–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao Y, Li W, Liu R, Guo Q, Li J, Bao Y, Zheng H, Jiang S and Hua B: Norcantharidin inhibits IL-6-induced epithelial-mesenchymal transition via the JAK2/STAT3/TWIST signaling pathway in hepatocellular carcinoma cells. Oncol Rep. 38:1224–1232. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen J, Wang S, Su J, Chu G, You H, Chen Z, Sun H, Chen B and Zhou M: Interleukin-32α inactivates JAK2/STAT3 signaling and reverses interleukin-6-induced epithelial-mesenchymal transition, invasion, and metastasis in pancreatic cancer cells. Onco Targets Ther. 9:4225–4237. 2016. View Article : Google Scholar : PubMed/NCBI
|
